At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 263 enrolled
Drug / intervention
Tesamorelin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-blind, Randomized, Placebo-controlled Extension Study Assessing the Efficacy and Long-term Safety of a 2 mg Dose of TH9507, a GHRH Analog, in HIV Subjects With Excess Abdominal Fat Accumulation
In Brief
A Phase 3 clinical trial evaluating Tesamorelin and Placebo for Tesamorelin for Lipodystrophy and HIV Infections. Completed, enrolled 263 participants across 47 sites in 6 countries.
Detailed Summary
Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLipodystrophy, HIV Infections
CountriesBelgium, Canada, France, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedFeb 2008
Primary CompletionOct 2008
TodayJul 2026
First PostedFeb 6, 2008
Enrollment StartAug 1, 2007
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 18.4 years ago
Interventions
Tesamorelindrug
Placebo for Tesamorelindrug